Brief: Alligator Bioscience Announces Positive Safety Data
30/09/2022 12:12
Sept 30 (Reuters) - Alligator Bioscience AB ATORX.ST :
* ANNOUNCES POSITIVE SAFETY DATA FROM 900 MG DOSE COHORT IN
ATOR-1017 PHASE 1 DOSE ESCALATION STUDY IN PATIENTS WITH
ADVANCED SOLID MALIGNANCIES
* ATOR-1017 DEMONSTRATED SAFETY AND TOLERABILITY AT DOSES UP
TO
900 MG
Source text for Eikon: ID:nMFNl8GBL
Further company coverage: ATORX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Alligator Bioscience AB
See all newsBrief: Alligator Bioscience Q1 Net Loss SEK 1.4 Million
Sweden's Alligator Bioscience posts Q1 net profit, narrows operating loss
Brief: Alligator Bioscience Q1 EBIT SEK -17.8 Million
Brief: Alligator Bioscience Signs LoI With Unicancer For Phase 3 Mitazalimab Development
Brief: Exercise Of Warrants Brings Alligator Bioscience Net Proceeds Of SEK 12 Mln